In this segment from Market Checkup, Motley Fool's health-care focused investing show, analysts David Williamson and Max Macaluso look at Merck's recent quarterly results. 

The Big Pharma posted declining revenue and net income, missing analyst estimates in the process. However, investors need to dig behind the top-line numbers to get a clear picture of Merck's potential. Guidance for 2014 was not a bad as feared, although it will be a transition year for the company. That doesn't mean the stock is stuck on timeout. Merck's pipeline has a lot of potential, and the company is striking collaboration agreements left and right.

In this video, David and Max dig through the quarterly results and discuss Merck's focus on immuno-oncology, its new partnership deals, and other interesting upcoming pipeline catalysts.

Could this change the way we treat cancer?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

David Williamson owns shares of Merck. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Compare Brokers